Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ianalumab versus placebo in diffuse cutaneous systemic sclerosis
2024-511933-36-00Phase 2Authorised
- Sponsor
- Novartis
- Start
- Jan 2025
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 25
01
Overview
Phase 2, randomised, double-blind trial in diffuse cutaneous systemic sclerosis (dcSSc) comparing Ianalumab with Placebo (2 arms). Primary endpoint: rCRISS25 response at Week 52. Planned start Jan 2025; status: authorised.
02
Drugs
ianalumab
03
Conditions
diffuse cutaneous systemic sclerosis (dcSSc)
Beyond the preview
Go deeper on 2024-511933-36-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-511933-36-00.